Targeting the Vascular Endothelial Growth Factor Pathway in the Treatment of Human Malignancy

REFERENCES

• Beecken W. D. C., Fernandez A., Joussen A. M., Achilles E. G., Flynn E., Lo K. M., Gillies S. D., Javaherian K., Folkman J., Shing Y. Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice. J. Natl. Can. Inst 2001; 93: 382–387
   Google Scholar
• Belotti D., Vergani V., Drudis T., Borsotti P., Pitelli M. R., Viale G., Giavazzi R., Taraboletti G. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res 1996; 2: 1843–1849
   PubMed Web of Science ®Google Scholar
• Benjamin L. E., Golijanin D., Itin A., Pode D., Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawl. J. Clin. Invest 1999; 103: 159–165
   PubMed Web of Science ®Google Scholar
• Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest 2003; 111: 1287–1295
   PubMed Web of Science ®Google Scholar
• Blackwell K. L., Haroon Z. A., Shan S., Saito W., Broadwater G., Greenberg C. S., Dewhirst M. W. Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clin. Can. Res 2000; 6: 4359–4364
   PubMed Web of Science ®Google Scholar
• Borgstrom P., Bourdon M. A., Hillan K. J., Sriramarao P., Ferrara N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. The Prostate 1998; 35: 1–10
   PubMed Web of Science ®Google Scholar
• Borgstrom P., Hillan K. J., Sriramarao P., Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996; 56: 4032–4039
   PubMed Web of Science ®Google Scholar
• Bos R., van Diest P. J., de Jong J. S., van der Groep P., van der Valk P., van der Wall E. Hypoxia-inducible factor-1α is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 2005; 46: 31–36
   PubMed Web of Science ®Google Scholar
• Brizel D. M., Scully S. P., Harrelson J. M., Layfield L. J., Bean J. M., Prosnitz L. R., Dewhirst M. W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56: 941–943
   PubMed Web of Science ®Google Scholar
• Browder T., Butterfield C. E., Draling B. M., Shi B., Marshall B., O'Reilly M. S., Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878–1886
   PubMed Web of Science ®Google Scholar
• Brown L. F., Berse B., Jackman R. W., Tognazzi K., Guidi A. J., Dvorak H. F., Senger D. R., Connolly J. L., Schnitt S. J. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol 1995; 26: 86–91
   PubMed Web of Science ®Google Scholar
• Brown L. F., Berse B., Jackman R. W., Tognazzi K., Manseau E. J., Dvorak H. F., Senger D. R. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol 1993; 143: 1255–1262
   PubMed Web of Science ®Google Scholar
• Brown L. F., Berse B., Jackman R. W., Tognazzi K., Manseau E. J., Senger D. R., Dvorak H. F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993; 53: 4727–4735
   PubMed Web of Science ®Google Scholar
• Casanovas O., Hicklin D. J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299–309
   PubMed Web of Science ®Google Scholar
• Chung K. Y, Saltz L. B. Antibody-based therapies for colorectal cancer. Oncologist 2005; 10: 701–709
   PubMed Web of Science ®Google Scholar
• Ciardiello F., Bianco R., Damiano V., Fontanini G., Caputo R., Pomatico G., de Placido S., Bianco A. R., Mendelsohn J., Tortora G. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res 2000; 6: 3739–3747
   PubMed Web of Science ®Google Scholar
• Cobleigh M. A., Langmuir V. K., Sledge G. W., Miller K. D., Haney L., Novotny W. F., Reimann J. D., Vassel A. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Sem. Oncol 2003; 30: 117–124
   PubMed Web of Science ®Google Scholar
• Connolly D. T., Heuvelman D. M., Nelson R., Olander J. V., Eppley B. L., Delfino J. J., Siegel N. R., Leimgruber R. M., Feder J. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest 1989; 84: 1470–1478
   PubMed Web of Science ®Google Scholar
• Dvorak H. F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol 2002; 20: 4368–4380
   PubMed Web of Science ®Google Scholar
• Ellis L. M., Takahashi Y., Fenoglio C. J., Cleary K. R., Bucana C. D., Evans D. B. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur. J. Cancer 1998; 34: 337–340
   Google Scholar
• Erber R., Hurnher A., Katsen A. D., Groth G., Kerger H., Hammes H. P., Menger M. D., Ullrich A., Vajkoczy P. Combined inhibition of VEGF- and PDGF-signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004; 18: 338–340
   PubMed Web of Science ®Google Scholar
• Escudier B., Szczylik C., Eisen T., Stadler W. M., Schwartz B., Shan M., Bukowski R. M. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (Bay 43–9006) in patients with advanced renal cell carcinoma (RCC). 2005 ASCO Proceedings 2005, Abstract Number 4510
   Google Scholar
• Escuin D., Kline E. R., Giannakakou P. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1α accumulation and activity by disrupting microtubule function. Cancer Res 2005; 65: 9021–9028
   PubMed Web of Science ®Google Scholar
• Fenton B. M., Paoni S. F., Ding I. Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors. Radiother. Oncol 2004; 72: 221–230
   PubMed Web of Science ®Google Scholar
• Ferrara N., Gerber H. P., LeCouter J. The biology of VEGF and its receptors. Nature Med 2003; 9: 669–676
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med 1971; 285: 1182–1186
   PubMed Web of Science ®Google Scholar
• Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst 1990; 82: 4–6
   PubMed Web of Science ®Google Scholar
• Folkman J., Merler E., Abernathy C., Williams G. Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med 1971; 133: 275–288
   PubMed Web of Science ®Google Scholar
• Garcea G., Lloyd T. D., Gescher A., Dennison A. R., Steward W. P., Berry D. P. Angiogenesis of gastrointestinal tumors and their metastases—a target for intervention?. Eur. J. Cancer 2004; 40: 1302–1313
   Google Scholar
• Gerber H. P., Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005; 65: 671–680
   PubMed Web of Science ®Google Scholar
• Giantonio B. J., Catalano P. J., Meropol N. J., O'Dwyer P. J., Mitchell E. P., Alberts S. R., Schwartz M. A., Benson A. B. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. 2005 ASCO Proceedings. 2005; Abstract Number 2
   Google Scholar
• Graeber T. G., Osmanian C., Jacks T., Housman D. E., Koch C. J., Lowe S. W., Giaccia A. J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996; 379: 88–91
   PubMed Web of Science ®Google Scholar
• Gupta K., Zhang J. Angiogenesis: a curse or cure?. Postgrad. Med. J 2005; 81: 236–242
   Google Scholar
• Hansen-Algenstaedt N., Stoll B. R., Padera T. P., Dolmans D. E., Hicklin D. J., Fukumura D., Jain R. K. Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res 2000; 60: 4556–4560
   PubMed Web of Science ®Google Scholar
• Harris A. Hypoxia- A key regulatory factor in tumour growth. Nat. Rev. Cancer 2002; 2: 38–47
   PubMed Web of Science ®Google Scholar
• Hasan J., Byers R., Jayson G. C. Intra-tumoural microvessel density in human solid tumors. Brit. J. Cancer 2002; 86: 1566–1577
   PubMed Web of Science ®Google Scholar
• Herbst R. S., Johnson D. H., Mininberg E., Carbone D. P., Henderson T., Kim E. S., Blumenschein G., Jr, Lee J. J., Liu D. D., Truong M. T., Hong W. K., Tran H., Tsao A., Xie D., Ramies D. A., Mass R., Seshagiri S., Eberhard D. A., Kelley S. K., Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small cell lung cancer. J. Clin. Oncol 2005; 23: 2544–2555
   PubMed Web of Science ®Google Scholar
• Hess-Stumpp H., Haberey M., Thierauch K. H. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. Chembiochemistry 2005; 6: 550–557
   PubMed Web of Science ®Google Scholar
• Hicklin D. J., Ellis L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol 2005; 23: 1011–1027
   PubMed Web of Science ®Google Scholar
• Hockel M., Schlenger K., Hockel S., Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999; 59: 4525–4528
   PubMed Web of Science ®Google Scholar
• Hockel M., Vaupel P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J. Nat. Cancer. Inst 2001; 93: 266–276
   PubMed Web of Science ®Google Scholar
• Holash J., Maisonpierre P. C., Compton D., Boland P., Alexander C. R., Zagzag D., Yancopoulos G. D., Wiegand S. J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994–1998
   PubMed Web of Science ®Google Scholar
• Hudis C. A. Clinical implications of antiangiogenic therapies. Oncology 2005; 19: 26–31
   Google Scholar
• Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus Irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med 2004; 350: 2335–2342
   PubMed Web of Science ®Google Scholar
• Inai T., Mancuso M., Hashizume H., Baffert F., Haskell A., Baluk P., Hu-Lowe D. D., Shalinsky D. R., Thurston G., Yancopoulos G. D., McDonald D. M. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol 2004; 165: 35–52
   PubMed Web of Science ®Google Scholar
• Inoue M., Hager J. H., Ferrara N., Gerber H. P., Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 2002; 1: 193–202
   PubMed Web of Science ®Google Scholar
• Jain R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58–62
   PubMed Web of Science ®Google Scholar
• Jain R. K., Baxter L. T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res 1988; 48: 7022–7032
   PubMed Web of Science ®Google Scholar
• Jayson G. C., Mulatero C., Ranson M., Zweit J., Jackson A., Broughton L., Wagstaff J., Hakansson L., Groenewegen G., Lawrance J., Tang M., Wauk L., Levitt D., Marreaud S., Lehmann F. F., Herold M., Zwierzina H. Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. Eur. J. Cancer 2002; 41: 555–563
   Google Scholar
• Johnson D. H., Fehrenbacher L., Novotny W. F., Herbst R. S., Nemunaitis J. J., Jablons D. M., Langer C. J., DeVore R. F., III, Gaudreault J., Damico L. A., Holmgren E., Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol 2004; 22: 2184–2191
   PubMed Web of Science ®Google Scholar
• Kabbinavar F. F., Schulz J., McCleod M., Patel T., Hamm J. T., Hecht J. R., Mass R., Perrou B., Nelson B., Novotny W. F. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J. Clin. Oncol 2005; 23: 3697–3705
   PubMed Web of Science ®Google Scholar
• Kabbinavar F., Hurwitz H. I., Fehrenbacher L., Meropol N. J., Novotny W. F., Lieberman G., Griffing S., Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/Leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol 2003; 21: 60–65
   PubMed Web of Science ®Google Scholar
• Kamba T., Tam B. Y., Hashizume H., Haskell A., Sennino B., Mancuso M., Norberg S. M., O'Brien S. M., Davis R. B., Gowen L. C., Anderson K. D., Thurston G., Joho S., Springer M. L., Kuo C. J., McDonald D. M. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am. J. Physiol. Heart Circ. Physiol 2006; 290: H560–H576
   PubMed Web of Science ®Google Scholar
• Karayiannakis A. J., Bolanaki H., Syrigos K. N., Asimakopoulos B., Polychronidis A., Anagnostoulis S., Simopoulos C. Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett 2003; 194: 119–124
   PubMed Web of Science ®Google Scholar
• Kim J. J., Tannock I. F. Repopulation of cancer cells during therapy: An important cause of treatment failure. Nat. Rev. Cancer 2005; 5: 516–525
   PubMed Web of Science ®Google Scholar
• Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D. J., Bohlen P., Kerbel R. S. Continous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest 2000; 105: R15–R24
   Web of Science ®Google Scholar
• Kopec J. A., Abrahamowicz M., Esdaile J. M. Randomized discontinuation trials: utility and efficiency. J. Clin. Epidemiol 1993; 46: 959–971
   PubMed Web of Science ®Google Scholar
• Krieg M., Haas R., Brauch H., Acker T., Flamme I., Plate K. H. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 2000; 19: 5435–5443
   PubMed Web of Science ®Google Scholar
• Lamszus K., Brockmann M. A., Eckerich C., Bohlen P., May C., Mangold U., Fillbrandt R., Westphal M. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin. Cancer Res 2005; 11: 4934–4940
   PubMed Web of Science ®Google Scholar
• Lee C. G., Heijn M., di Tomaso E., Griffon-Etienne G., Ancukiewicz M., Koike C., Park K. R., Ferrara N., Jain R. K., Suit H. D., Boucher Y. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000; 60: 5565–5570
   PubMed Web of Science ®Google Scholar
• Lee L., Sharma S., Morgan B., Allegrini P., Schnell C., Brueggen J., Cozens R., Horsfield M., Guenther C., Steward W. P., Drevs J., Leebwohl D., Wood J., McSheehy P. M. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother. Pharmacol 2005; 57: 761–771
   Google Scholar
• Liang W. C., Wu X., Peale F. V., Lee C. V., Meng G., Gutierrez J., Fu L., Malik A. K., Gerber H. P., Ferrara N., Fuh G. Cross-species VEGF-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol. Chem 2006; 281: 951–961
   PubMed Web of Science ®Google Scholar
• Lorincz T., Toth J., Szendroi M., Timar J. Microvascular density of breast cancer in bone metastasis: Influence of therapy. Anticancer Res 2005; 25: 3075–3082
   Google Scholar
• Lu D., Shen J., Vil M. D., Zhang H., Jimenez X., Bohlen P., Witte L., Zhu Z. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J. Biol. Chem 2003; 278: 43496–43507
   PubMed Web of Science ®Google Scholar
• Luttun A., Tjwa M., Moons L., Wu Y., Angelillo-Scherrer A., Liao F., Nagy J. A., Hooper A., Priller J., De Klerck B., Compernolle V., Daci E., Bohlen P., Dewerchin M., Herbert J. M., Fava R., Matthys P., Carmeliet G., Collen D., Dvorak H. F., Hicklin D. J., Carmeliet P. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nature Med 2002; 8: 831–840
   PubMed Web of Science ®Google Scholar
• Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., Chadburn A., Heissig B., Marks W., Witte L., Wu Y., Hicklin D., Zhu Z., Hackett N. R., Crystal R. G., Moore M. A. S., Hajjar K. A., Manova K., Benezra R., Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Med 2001; 7: 1194–1201
   PubMed Web of Science ®Google Scholar
• Magne N., Marcy P. Y., Chamorey E., Guardiola E., Pivot X., Schneider M., Demard F., Bensadoun R. J. Concomitant twice-a-day radiotherapy and chemotherapy in unresectable head and neck cancer patients: a long-term quality of life analysis. Head Neck 2001; 23: 678–682
   Google Scholar
• Mandriota S. J., Jussila L., Jeltsch M., Compagni A., Baetens D., Prevo R., Banerji S., Huarte J., Montesano R., Jackson D. G., Orci L., Alitalo K., Christofori G., Pepper M. S. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumor metastasis. EMBO 2001; 20: 672–682
   PubMed Web of Science ®Google Scholar
• Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R., Moller N. P., Risau W., Ullrich A. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993; 26: 835–846
   Google Scholar
• Miller K. D., Chap L. I., Holmes F. A., Cobleigh M. A., Marcom P. K., Fehrenbacher L., Dickler M., Overmoyer B. A., Reimann J. D., Sing A. P., Langmuir V., Rugo H. S. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol 2005; 23: 792–799
   PubMed Web of Science ®Google Scholar
• Miller K. D., Trigo J. M., Wheeler C., Barge A., Rowbottom J., Sledge G., Baselga J. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin. Cancer Res 2005; 11: 3369–3376
   PubMed Web of Science ®Google Scholar
• Miodonski A., Kus J., Olszewski E., Tyrankiewicz R. Scanning electron microscopic studies on blood vessels in cancer of the larynx. Arch. Otolaryngol 1980; 106: 321–332
   Google Scholar
• Mooteri S., Rubin D., Leurgans S., Jakate S., Drab E., Saclarides T. Tumor angiogenesis in primary and metastatic colorectal cancers. Dis. Colon Rectum 1996; 39: 1073–1080
   Google Scholar
• Motzer R. J., Michaelson M. D., Redman B. G., Hudes G. R., Wilding G., Figlin R. A., Ginsberg M. S., Kim S. T., Baum C. M., DePrimo S. E., Li J. Z., Bello C. L., Theuer C. P., George D. J., Rini B. I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol 2006; 24: 16–24
   PubMed Web of Science ®Google Scholar
• Mross K., Drevs J., Muller M., Medinger M., Marme D., Hennig J., Morgan B., Lebwohl D., Masson E., Ho Y. Y., Gunther C., Laurent D., Unger C. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumors. Eur. J. Cancer 2002; 41: 1291–1299
   Google Scholar
• Nelson D. A., Tan T. T., Rabson A. B., Anderson D., Degenhardt K., White E. Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev 2004; 18: 2095–2107
   PubMed Web of Science ®Google Scholar
• Niedergethmann M., Hildenbrand R., Wostbrock B., Hartel M., Sturm J. W., Richter A., Post S. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 2002; 25: 122–129
   PubMed Web of Science ®Google Scholar
• Paavonen K., Puolakkainen P., Jussila L., Jahkola T., Alitalo K. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am. J. Pathol 2000; 156: 1499–1504
   PubMed Web of Science ®Google Scholar
• Park J. E., Keller G. A., Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell 1993; 4: 1317–1326
   PubMed Web of Science ®Google Scholar
• Pezzella F., Pastorino U., Tagliabue E., Andreola S., Sozzi G., Gasparini G., Menard S., Gatter K. C., Harris A. L., Fox S., Buyse M., Pilotti S., Pierotti M., Rilke F. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am. J. Pathol 1997; 151: 1417–1423
   PubMed Web of Science ®Google Scholar
• Poon R. T., Fan S. T., Wong J. Clinical implication of circulating angiogenic factors in cancer patients. J. Clin. Oncol 2001; 19: 1207–1225
   PubMed Web of Science ®Google Scholar
• Prewett M., Huber J., Li Y., Santiago A., O'Connor W., King K., Overholser J., Hooper A., Pytowski B., Witte L., Bohlen P., Hicklin D. J. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59: 5209–5218
   PubMed Web of Science ®Google Scholar
• Ratain M. J., Eisen T., Stadler W. M., Flaherty K. T., Gore M., Desai A., Patnaik A., Xiong H. Q., Schwartz B., O'Dwyer P. Final findings from a phase II, placebo-controlled, randomized discontinuation trail (RDT) of sorafenib (Bay 43–9006) in patients with advanced renal cell carcinoma (RCC). 2005 ASCO Proceedings. 2005; Abstract Number 4544
   Google Scholar
• Relf M., LeJeune S., Scott P. A., Fox S., Smith K., Leek R., Moghaddam A., Whitehouse R., Bicknell R., Harris A. L. Expression of the angiogenic factors vascular endothelial growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963–969
   PubMed Web of Science ®Google Scholar
• Renton A., Llanos S., Lu X. Hypoxia induces p53 through a pathway distinct from most DNA-damaging and stress-inducing agents. Carcinogenesis 2003; 24: 1177–1182
   Google Scholar
• Rich J. N., Sathornsumetee S., Keir S. T., Kieran M. W., Laforme A., Kaipainen A., McLendon R. E., Graner M. W., Rasheed B. K. A., Wang L., Reardon D. A., Ryan A. J., Wheeler C., Dimery I., Bigner D. D., Friedman H. S. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin. Cancer Res 2005; 11: 8145–8157
   PubMed Web of Science ®Google Scholar
• Ryschich E., Schmidt J., Hammerling G. J., Klar E., Ganss R. Tranformation of the microvascular system during multistage tumorigenesis. Int. J. Cancer 2002; 97: 719–725
   PubMed Web of Science ®Google Scholar
• Senger D. R., Perruzzi C. A., Feder J., Dvorak H. F. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986; 46: 5629–5632
   PubMed Web of Science ®Google Scholar
• Seo Y., Baba H., Fukuda T., Takashima M., Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000; 88: 2239–2245
   PubMed Web of Science ®Google Scholar
• Sini P., Wyder L., Schnell C., O'Reilly T., Littlewood A., Brandt R., Hynes N. E., Wood J. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Clin. Cancer Res 2005; 11: 4521–4532
   PubMed Web of Science ®Google Scholar
• Stacker S. A., Caesar C., Baldwin M. E., Thornton G. E., Jackson D. G., Nishikawa S., Kubo H., Achen M. G. VEGF-D promotes the metastatic spread of tumor cells via lymphatics. Nature Med 2001; 7: 186–191
   PubMed Web of Science ®Google Scholar
• Stadler W. M., Kuzel T., Shapiro C., Sosman J., Clark J., Vogelzang N. J. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J. Clin. Oncol 1999; 17: 2541–2545
   PubMed Web of Science ®Google Scholar
• Stessels F., van den Eynden G., van der Auwera I., Salgado R., van den Heuvel E., Harris A. L., Jackson D. G., Colpaert C. G., van Marck E. A., Dirix L. Y., Vermeulen P. B. Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br. J. Cancer 2004; 90: 1429–1436
   PubMed Web of Science ®Google Scholar
• Sundberg C., Nagy J. A., Brown L. F., Feng D., Eckelhoefer I. A., Manseau E. J., Dvorak A. M., Dvorak H. F. Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. Am. J. Pathol 2001; 158: 1145–1160
   PubMed Web of Science ®Google Scholar
• Takahashi Y., Kitadai Y., Bucana C. D., Cleary K. R., Ellis L. M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55: 3964–3968
   PubMed Web of Science ®Google Scholar
• Teicher B. A. Angiogenesis and cancer metastases: therapeutic approaches. Crit. Rev. Oncol./Hematol 1995; 20: 9–39
   PubMedGoogle Scholar
• Teicher B. A. A systems approach to cancer therapy. Cancer. Met. Rev 1996; 15: 247–272
   PubMed Web of Science ®Google Scholar
• Therasse P., Arbuck S. G., Eisenhauer E. A., Wanders J., Kaplan R. S., Rubinstein L., Verweij J., Van Glabbeke M., van Oosterom A. T., Christian M. C., Gwyther S. G. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst 2000; 92: 205–216
   PubMed Web of Science ®Google Scholar
• Tong R. T., Boucher Y., Kozin S. V., Winkler F., Hicklin D. J., Jain R. K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64: 3731–3736
   PubMed Web of Science ®Google Scholar
• Tonra J. R., Deevi D. S., Corcoran E., Li H., Wang S., Carrick F. E., Hicklin D. J. Synergistic antitumor effects of combined epidermal growth factor and vascular endothelial growth factor receptor-2 targeted therapy. Clin. Cancer Res 2006; 12: 2197–2207
   PubMed Web of Science ®Google Scholar
• Tyagi P. Bevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: preliminary results from the ECOG 4599 trial. Clin. Lung Cancer 2005; 6: 276–278
   PubMedGoogle Scholar
• Van den Eynden G. G., Van der Auwera I., Van Laere S. J., Colpaert C. G., Turley H., Harris A. L., van Dam P., Dirix L. Y., Vermeulen P. B., van Marck E. A. Angiogenesis and hypoxia in lymph node metastasis is predicted by the angiogenesis and hypoxia in the primary tumor in patients with breast cancer. Br. J. Cancer 2005; 93: 1128–1136
   Google Scholar
• Vaupel P. The role of hypoxia-induced factors in tumor progression. The Oncologist 2004; 9: 10–17
   PubMed Web of Science ®Google Scholar
• Vaupel P., Kelleher D. K., Hockel M. Oxygenation status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Sem. Oncol 2001; 28: 29–35
   PubMed Web of Science ®Google Scholar
• Veikkola T., Karkkainen M., Claesson-Welsh L., Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000; 60: 203–212
   PubMed Web of Science ®Google Scholar
• Willett C. G., Boucher Y., di Tomaso E., Duda D. G., Munn L. L., Tong R. T., Chung D. C., Sahani D. V., Kalva S. P., Kozin S. V., Mino M., Cohen K. S., Scadden D. T., Hartford A. C., Fischman A. J., Clark J. W., Ryan D. P., Zhu A. X., Blaszkowsky L. S., Chen H. X., Shellito P. C., Lauwers G. Y., Jain R. K. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Med 2004; 10: 145–147
   PubMed Web of Science ®Google Scholar
• Williams K. J., Telfer B. A., Xenaki D., Sheridan M. R., Desbaillets I., Peters H. J., Honess D., Harris A. L., Dachs G. U., van der Kogel A., Stratford I. J. Enhanced response to radiotherapy in tumors deficient in the function of hypoxia-inducible factor-1. Radiother. Oncol 2005; 75: 89–98
   PubMed Web of Science ®Google Scholar
• Winkler F., Kozin S. V., Tong R. T., Chae S. S., Booth M. F., Garkavtsev I., Xu L., Hicklin D. J., Fukumura D., di Tomaso E., Munn L. L., Jain R. K. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6: 553–563
   PubMed Web of Science ®Google Scholar
• Withers H. R., Peters L. J., Taylor J. M., Owen J. B., Morrison W. H., Schultheiss T. E., Keane T., O'sullivan B., Van Dyk J., Gupta N., Wang C. C., Jones C. U., Doppke K. P., Myint S., Thompson M., Parsons J. T., Mendenhall W. M., Dische S., Aird E. G. A., Henk J. M., Bidmead M. A. M., Svoboda V., Chon Y., Hanlon A. L., Peters T. L., Hanks G. E. Local control of carcinoma of the tonsil by radiation therapy: an analysis of patterns of fractionation in nine institutions. Int. J. Rad. Oncol. Phys 1995; 33: 549–562
   PubMed Web of Science ®Google Scholar
• Witte L., Hicklin D. J., Zhu Z., Pytowski B., Kotanides H., Rockwell P., Bohlen P. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 1998; 17: 155–161
   PubMed Web of Science ®Google Scholar
• Yang J. C., Haworth L., Sherry R. M., Hwu P., Schwartzentruber D. J., Topalian S. L., Steinberg S. M., Chen H. X., Rosenberg S. A. A randomized trial of bevacizumab, and anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med 2003; 349: 427–434
   PubMed Web of Science ®Google Scholar
• Yu J. L., Rak J. W., Carmeliet P., Nagy A., Kerbel R. S., Coomber B. L. Heterogeneous vascular dependence of tumor populations. Am. J. Pathol 2001; 158: 1325–1334
   PubMedGoogle Scholar
• Yuan F., Chen Y., Dellian M., Safabakhsh N., Ferrara N., Jain R. K. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. USA 1996; 93: 14765–14770
   PubMed Web of Science ®Google Scholar